
Opinion|Videos|December 11, 2024
Rationale for Combining Elacestrant With Targeted Agents
Author(s)Hope S. Rugo, MD
A panelist discusses how combining elacestrant with targeted therapies like CDK4/6 inhibitors or PI3K inhibitors could potentially enhance its efficacy and overcome resistance mechanisms in ER+/HER2– MBC treatment.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















